Medical - Care Facilities
Compare Stocks
4 / 10Stock Comparison
AMS vs DBVT vs ALKS vs ARAY
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Medical - Devices
AMS vs DBVT vs ALKS vs ARAY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Biotechnology | Medical - Devices |
| Market Cap | $13M | $1712.35T | $5.90B | $35M |
| Revenue (TTM) | $29M | $0.00 | $1.56B | $429M |
| Net Income (TTM) | $-2M | $-168M | $153M | $-46M |
| Gross Margin | 25.0% | — | 65.4% | 26.8% |
| Operating Margin | -12.3% | — | 12.3% | -5.1% |
| Forward P/E | 6.1x | — | 24.8x | — |
| Total Debt | $23M | $22M | $70M | $176M |
| Cash & Equiv. | $11M | $194M | $1.12B | $57M |
AMS vs DBVT vs ALKS vs ARAY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| American Shared Hos… (AMS) | 100 | 109.2 | +9.2% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
| Alkermes plc (ALKS) | 100 | 216.4 | +116.4% |
| Accuray Incorporated (ARAY) | 100 | 14.0 | -86.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMS vs DBVT vs ALKS vs ARAY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AMS is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 32.9%, EPS growth 245.9%, 3Y rev CAGR 17.1%
- -4.7% 10Y total return vs ALKS's -11.0%
- 32.9% revenue growth vs DBVT's -100.0%
- Better valuation composite
DBVT is the clearest fit if your priority is income & stability.
- Dividend streak 0 yrs, beta 1.26
- +110.4% vs ARAY's -78.4%
ALKS carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- Beta 1.06, current ratio 3.55x
- 9.8% margin vs ARAY's -10.8%
- Beta 1.06 vs ARAY's 2.42, lower leverage
ARAY lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.9% revenue growth vs DBVT's -100.0% | |
| Value | Better valuation composite | |
| Quality / Margins | 9.8% margin vs ARAY's -10.8% | |
| Stability / Safety | Beta 1.06 vs ARAY's 2.42, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +110.4% vs ARAY's -78.4% | |
| Efficiency (ROA) | 5.4% ROA vs DBVT's -89.0% |
AMS vs DBVT vs ALKS vs ARAY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
AMS vs DBVT vs ALKS vs ARAY — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 2 of 6 categories
ARAY leads 1 • DBVT leads 1 • AMS leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to ARAY's -10.8%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $29M | $0 | $1.6B | $429M |
| EBITDAEarnings before interest/tax | $2M | -$112M | $212M | -$15M |
| Net IncomeAfter-tax profit | -$2M | -$168M | $153M | -$46M |
| Free Cash FlowCash after capex | -$10M | -$151M | $392M | -$28M |
| Gross MarginGross profit ÷ Revenue | +25.0% | — | +65.4% | +26.8% |
| Operating MarginEBIT ÷ Revenue | -12.3% | — | +12.3% | -5.1% |
| Net MarginNet income ÷ Revenue | -7.6% | — | +9.8% | -10.8% |
| FCF MarginFCF ÷ Revenue | -34.7% | — | +25.1% | -6.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | — | +28.2% | -7.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.7% | +91.5% | -4.1% | -6.1% |
Valuation Metrics
ARAY leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
At 6.1x trailing earnings, AMS trades at a 75% valuation discount to ALKS's 24.8x P/E. On an enterprise value basis, AMS's 7.5x EV/EBITDA is more attractive than ALKS's 17.3x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $13M | $1712.35T | $5.9B | $35M |
| Enterprise ValueMkt cap + debt − cash | $25M | $1712.35T | $4.9B | $154M |
| Trailing P/EPrice ÷ TTM EPS | 6.09x | -0.76x | 24.76x | -18.91x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | 0.93x | — | — | — |
| EV / EBITDAEnterprise value multiple | 7.51x | — | 17.25x | 10.99x |
| Price / SalesMarket cap ÷ Revenue | 0.46x | — | 4.00x | 0.08x |
| Price / BookPrice ÷ Book value/share | 0.45x | 0.66x | 3.28x | 0.37x |
| Price / FCFMarket cap ÷ FCF | — | — | 12.28x | — |
Profitability & Efficiency
ALKS leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARAY's 2.17x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -7.9% | -130.2% | +8.8% | -77.5% |
| ROA (TTM)Return on assets | -3.8% | -89.0% | +5.4% | -10.1% |
| ROICReturn on invested capital | -5.8% | — | +18.9% | +3.0% |
| ROCEReturn on capital employed | -6.4% | -145.7% | +14.2% | +2.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.77x | 0.13x | 0.04x | 2.17x |
| Net DebtTotal debt minus cash | $12M | -$172M | -$1.0B | $119M |
| Cash & Equiv.Liquid assets | $11M | $194M | $1.1B | $57M |
| Total DebtShort + long-term debt | $23M | $22M | $70M | $176M |
| Interest CoverageEBIT ÷ Interest expense | -1.35x | -189.82x | 32.30x | -1.86x |
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $606 for ARAY. Over the past 12 months, DBVT leads with a +110.4% total return vs ARAY's -78.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs ARAY's -56.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -4.3% | +4.9% | +25.3% | -65.5% |
| 1-Year ReturnPast 12 months | -27.4% | +110.4% | +16.5% | -78.4% |
| 3-Year ReturnCumulative with dividends | -28.0% | +19.7% | +14.5% | -91.8% |
| 5-Year ReturnCumulative with dividends | -41.1% | -69.1% | +60.9% | -93.9% |
| 10-Year ReturnCumulative with dividends | -4.7% | -87.0% | -11.0% | -94.5% |
| CAGR (3Y)Annualised 3-year return | -10.4% | +6.2% | +4.6% | -56.6% |
Risk & Volatility
Evenly matched — AMS and ALKS each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMS is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than ARAY's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs ARAY's 14.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.02x | 1.26x | 1.06x | 2.42x |
| 52-Week HighHighest price in past year | $3.11 | $26.18 | $36.60 | $2.10 |
| 52-Week LowLowest price in past year | $1.25 | $7.53 | $25.17 | $0.28 |
| % of 52W HighCurrent price vs 52-week peak | +64.6% | +76.3% | +96.7% | +14.0% |
| RSI (14)Momentum oscillator 0–100 | 63.8 | 48.1 | 60.2 | 58.4 |
| Avg Volume (50D)Average daily shares traded | 138K | 252K | 2.3M | 1.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: DBVT as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 24.3% for ALKS (target: $44).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | — |
| Price TargetConsensus 12-month target | — | $46.33 | $44.00 | — |
| # AnalystsCovering analysts | — | 15 | 28 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | 0 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | 0.0% |
ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ARAY leads in 1 (Valuation Metrics). 1 tied.
AMS vs DBVT vs ALKS vs ARAY: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is AMS or DBVT or ALKS or ARAY a better buy right now?
For growth investors, American Shared Hospital Services (AMS) is the stronger pick with 32.
9% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). American Shared Hospital Services (AMS) offers the better valuation at 6. 1x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AMS or DBVT or ALKS or ARAY?
On trailing P/E, American Shared Hospital Services (AMS) is the cheapest at 6.
1x versus Alkermes plc at 24. 8x.
03Which is the better long-term investment — AMS or DBVT or ALKS or ARAY?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -93. 9% for Accuray Incorporated (ARAY). Over 10 years, the gap is even starker: AMS returned -4. 7% versus ARAY's -94. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AMS or DBVT or ALKS or ARAY?
By beta (market sensitivity over 5 years), American Shared Hospital Services (AMS) is the lower-risk stock at -0.
02β versus Accuray Incorporated's 2. 42β — meaning ARAY is approximately -15516% more volatile than AMS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.
05Which is growing faster — AMS or DBVT or ALKS or ARAY?
By revenue growth (latest reported year), American Shared Hospital Services (AMS) is pulling ahead at 32.
9% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: American Shared Hospital Services grew EPS 245. 9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, AMS leads at 17. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AMS or DBVT or ALKS or ARAY?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -0. 3% for Accuray Incorporated — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -9. 9% for AMS. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Which pays a better dividend — AMS or DBVT or ALKS or ARAY?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is AMS or DBVT or ALKS or ARAY better for a retirement portfolio?
For long-horizon retirement investors, American Shared Hospital Services (AMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
02)). Accuray Incorporated (ARAY) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMS: -4. 7%, ARAY: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between AMS and DBVT and ALKS and ARAY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AMS is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; ARAY is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.